TAKEDA PHARMACEUTICAL COMPANY LIMITED Unternehmen Takeda Pharmaceutical Company Limited Mexican S.E.
Aktien
A1CWZF
US8740602052
TAK N
Pharmazeutika
|
Schlusskurs
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 240,5 MXN | -1,84 % |
|
-.--% | +0,33 % |
Kurzporträt
- Verkauf von Arzneimitteln und Verbraucherpflegeprodukten;
- Dienstleistungen.
Der Nettoumsatz verteilt sich geographisch wie folgt: Japan (17,5%), Asien (5%), die Vereinigten Staaten (49%), Europa und Kanada (20,8%), Lateinamerika (3,8%), Russland und GUS (1,8%) und Sonstige (2,1%).
Mitarbeiterzahl: 49 095
Umsatz nach Geschäftsbereich
| JPY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
Gastroenterology - Entyvio
17,4
%
| 521 778 | 14,6 % | 702 744 | 17,4 % | +34,68 % |
Plasma-derived Therapies - Immunoglobulin
13,0
%
| 385 864 | 10,8 % | 522 211 | 13,0 % | +35,34 % |
Neuroscience - Vyvanse/Elvanse
11,4
%
| 327 052 | 9,2 % | 459 289 | 11,4 % | +40,43 % |
Other - Others
9,1
%
| 515 164 | 14,4 % | 364 968 | 9,1 % | -29,15 % |
Rare Genetic Diseases and Others - Tacxiro
3,8
%
| - | - | 151 800 | 3,8 % | - |
Plasma-derived Therapies - Albumin
3,0
%
| 90 035 | 2,5 % | 121 446 | 3,0 % | +34,89 % |
Rare Blood Disease - advertise
2,9
%
| 118 491 | 3,3 % | 118 188 | 2,9 % | -0,26 % |
Oncology - Leuplin/Enantone
2,8
%
| 106 459 | 3,0 % | 111 311 | 2,8 % | +4,56 % |
Gastroenterology - Takecab-f
2,7
%
| 102 397 | 2,9 % | 108 719 | 2,7 % | +6,17 % |
Neuroscience - Trintelix
2,5
%
| 82 315 | 2,3 % | 100 081 | 2,5 % | +21,58 % |
Gastroenterology - Gattex/Revestive
2,3
%
| 75 751 | 2,1 % | 93 076 | 2,3 % | +22,87 % |
Oncology - Ninlaro
2,3
%
| 91 203 | 2,6 % | 92 691 | 2,3 % | +1,63 % |
Rare Genetic Diseases and Others - Ella Place
2,1
%
| 73 119 | 2,0 % | 85 321 | 2,1 % | +16,69 % |
Oncology - Adcetris
2,1
%
| 69 190 | 1,9 % | 83 937 | 2,1 % | +21,31 % |
Neuroscience - Others
1,9
%
| 72 926 | 2,0 % | 78 341 | 1,9 % | +7,43 % |
Other - Azilva
1,8
%
| 76 297 | 2,1 % | 72 897 | 1,8 % | -4,46 % |
Gastroenterology - Others
1,8
%
| 82 877 | 2,3 % | 72 388 | 1,8 % | -12,66 % |
Gastroenterology - Dexilant
1,7
%
| 50 763 | 1,4 % | 69 371 | 1,7 % | +36,66 % |
Rare Genetic Diseases and Others - Replagal
1,7
%
| 51 714 | 1,4 % | 66 741 | 1,7 % | +29,06 % |
Rare Blood Disease - Adynovate/Advynovi
1,7
%
| 60 726 | 1,7 % | 66 553 | 1,7 % | +9,60 % |
Rare Genetic Diseases and Others - Others
1,4
%
| - | - | 55 989 | 1,4 % | - |
Oncology - Others
1,3
%
| 43 329 | 1,2 % | 51 551 | 1,3 % | +18,98 % |
Rare Genetic Diseases and Others - Biprib
1,2
%
| 42 408 | 1,2 % | 48 372 | 1,2 % | +14,06 % |
Oncology - Iclusig
1,2
%
| 34 860 | 1,0 % | 47 206 | 1,2 % | +35,42 % |
Rare Blood Disease - Other
1,2
%
| 53 013 | 1,5 % | 46 367 | 1,2 % | -12,54 % |
Gastroenterology - Pantoloc/Controloc
1,1
%
| 40 275 | 1,1 % | 45 518 | 1,1 % | +13,02 % |
Rare Blood Disease - Fiber
1,0
%
| 39 162 | 1,1 % | 41 268 | 1,0 % | +5,38 % |
Plasma - Derived Immune Disease Treatment - Other
0,9
%
| 31 052 | 0,9 % | 34 786 | 0,9 % | +12,02 % |
Oncology - Velcade
0,7
%
| 110 046 | 3,1 % | 27 759 | 0,7 % | -74,78 % |
Oncology - Arumbrig
0,5
%
| 13 644 | 0,4 % | 20 556 | 0,5 % | +50,66 % |
Rare Blood Disease - Hemofil/Immunate/Immunine
0,5
%
| - | - | 19 581 | 0,5 % | - |
Other - Rotrigger
0,4
%
| 32 690 | 0,9 % | 16 732 | 0,4 % | -48,82 % |
Rare Hematology - Recombinate
0,3
%
| 12 297 | 0,3 % | 12 762 | 0,3 % | +3,78 % |
Rare Genetic Diseases and Others - Livetencity
0,3
%
| - | - | 10 501 | 0,3 % | - |
Oncology - Exkivity
0,1
%
| - | - | 3 732 | 0,1 % | - |
Gastroenterology - Alofisel
0,1
%
| 1 843 | 0,1 % | 2 725 | 0,1 % | +47,86 % |
Umsatz je Region
| JPY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
United States
52,2
%
| 1 714 421 | 48,0 % | 2 103 772 | 52,2 % | +22,71 % |
Europe and Canada
20,9
%
| 739 168 | 20,7 % | 842 668 | 20,9 % | +14,00 % |
Japan
12,7
%
| 658 983 | 18,5 % | 512 043 | 12,7 % | -22,30 % |
Asia
5,6
%
| 196 964 | 5,5 % | 225 007 | 5,6 % | +14,24 % |
Latin America
4,0
%
| 128 467 | 3,6 % | 160 375 | 4,0 % | +24,84 % |
Other
2,4
%
| 68 945 | 1,9 % | 95 182 | 2,4 % | +38,05 % |
Russia / Commonwealth of Independent States
2,2
%
| 62 057 | 1,7 % | 88 431 | 2,2 % | +42,50 % |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 01.04.14 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 01.02.22 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 01.01.12 |
| Chief Tech/Sci/R&D Officer | 69 | 01.04.15 | |
Andrew Plump
CTO | Chief Tech/Sci/R&D Officer | 58 | 01.02.15 |
Norimasa Takeda
CMP | Compliance Officer | - | - |
| Director/Board Member | 53 | 01.01.15 | |
Haruhiko Hirate
IRO | Public Communications Contact | - | - |
Takashi Okubo
IRO | Public Communications Contact | - | - |
| Investor Relations Contact | - | 01.06.11 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
| Director/Board Member | 71 | 01.06.16 | |
Ian Clark
BRD | Director/Board Member | 62 | 01.01.19 |
Steven Gillis
BRD | Director/Board Member | 71 | 01.01.19 |
John Maraganore
BRD | Director/Board Member | 60 | 01.06.22 |
Emiko Higashi
BRD | Director/Board Member | 64 | 01.06.16 |
Christophe Weber
CEO | Chief Executive Officer | 57 | 01.04.14 |
Andrew Plump
CTO | Chief Tech/Sci/R&D Officer | 58 | 01.02.15 |
| Director/Board Member | 53 | 01.01.15 | |
Kimberly Reed
BRD | Director/Board Member | 53 | 01.06.22 |
Miki Tsusaka
BRD | Director/Board Member | 61 | 01.04.23 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 0 | 1 582 418 725 | 1 568 501 201 ( 99,12 %) | 13 405 261 ( 0,8471 %) | 99,12 % |
Unternehmensbesitz
| Name | Aktien | % | Bewertung |
|---|---|---|---|
| 7 511 300 | 0,47% | 199 463 248 $ | |
HILLEVAX, INC. 13,52% | 6 724 000 | 13,52% | 81 629 360 $ |
DENALI THERAPEUTICS INC. 2,96% | 4 214 559 | 2,96% | 78 222 215 $ |
| 2 204 000 | 7,21% | 33 085 588 $ | |
OVID THERAPEUTICS INC. 12,38% | 8 781 996 | 12,38% | 26 872 908 $ |
| 2 790 480 | 4,77% | 26 286 322 $ | |
WAVE LIFE SCIENCES LTD. 0,90% | 1 096 892 | 0,90% | 6 778 793 $ |
NOILE-IMMUNE BIOTECH INC. 18,76% | 8 119 800 | 18,76% | 6 768 828 $ |
Unternehmenskontakt
Takeda Pharmaceutical Co., Ltd.
4-1-1 Dosho-machi Chuo-Ku
540-8645, Osaka
+81 3 3278 2111
http://www.takeda.co.jp
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Shire Biotech India Pvt Ltd.
| |
Takeda Belgium NV
 Takeda Belgium NV Medical DistributorsDistribution Services Founded in 1835, Takeda Belgium NV is a subsidiary of Takeda Pharmaceutical Co., Ltd. The company is based in Zaventem, Belgium and focuses on providing better healthcare solutions for their patients. Takeda Belgium's mission is centered around the question of how they can do more for their patients. |
Medical Distributors
|
Takeda Pharmaceuticals U.S.A., Inc.
 Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals U.S.A., Inc. develops and markets pharmaceutical products. It offers metabolic and cardiovascular, respiratory and immunology, central nervous system, oncology, and general medicine products. The company was founded in 1998 and is headquartered in Deerfield, IL. |
Pharmaceuticals: Major
|
Shire Ireland Finance Trading Ltd.
| |
Shire Biotech UK Holdings Ltd.
 Shire Biotech UK Holdings Ltd. Financial ConglomeratesFinance Part of Takeda Pharmaceutical Co., Ltd., Shire Biotech UK Holdings Ltd. is an investment holding company. Shire Biotech UK Holdings Ltd. is based in London, UK. Founded in 2017, Shire Biotech UK Holdings functions as an investment holding company. |
Financial Conglomerates
|
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. |
Financial Conglomerates
|
Takeda Pharmaceuticals International AG
 Takeda Pharmaceuticals International AG Pharmaceuticals: MajorHealth Technology Takeda Pharmaceuticals International GmbH develops, manufactures, and distributes pharmaceutical products. It offers medicines in therapeutic areas, such as, cardiovascular and metabolic, oncology, central nervous system, respiratory and immunology, general medicine, and vaccines. The firm also provides packaging, development, contract manufacturing and quality control services. Takeda Pharmaceuticals International was founded in 1874 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Takeda Manufacturing Austria AG
 Takeda Manufacturing Austria AG Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda Manufacturing Austria AG manufactures and supplies vital medicines and medical devices. The company is based in Vienna, Austria. |
Pharmaceuticals: Major
|
Takeda GmbH
 Takeda GmbH Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Takeda GmbH is a German pharmaceutical company that manufactures pharmaceutical products. The company is based in Konstanz, Germany. The CEOs are Wolfgang Eck, Uwe Hoffmeister, Roland Kurney. The company was founded in 1873. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
| % 1. Jan. | Kap. | |
|---|---|---|
| +52,93 % | 803 Mrd. | |
| +41,13 % | 631 Mrd. | |
| -7,08 % | 351 Mrd. | |
| +17,40 % | 324 Mrd. | |
| +10,58 % | 303 Mrd. | |
| +16,40 % | 243 Mrd. | |
| +2,09 % | 228 Mrd. | |
| +10,35 % | 217 Mrd. | |
| +6,24 % | 164 Mrd. |
- Börse
- Aktien
- 853849 Aktie
- A1CWZF Aktie
- Unternehmen Takeda Pharmaceutical Company Limited
